

LIST OF SESSIONS

WORKSHOPS

Cervical cancer screening

L. Cloostermans (Netherlands) • M. Rebolj (UK) • S. Van Dijk (Netherlands)

Vulvar diseases

M. Bleeker (Netherlands) • M. Hampl (Germany)

Colposcopy course

J. Bornstein (Israel) • A. Singer (UK)

Anal cancer: screening guidelines

A. Nyitray (USA) • J. Palefsky (USA)

CERVICAL CANCER CONTROL

Global inequalities in cervical cancer prevention: Are we currently on the path to cervical cancer elimination?

M. Brisson (Canada) • M. Drolet (Canada)

3rd edition of the European Guidelines for quality assurance in cervical cancer screening

P. Basu (France)

Strategies for faster cervical cancer elimination

J. Dillner (Sweden)

SCREENING

RISCC and PERCH: EU Initiatives to eliminate cervical cancer

M. Arbyn (Belgium) • H. Berkhof (Netherlands) • J. Dillner (Sweden)

Quality assurance measures in countries that switched to HPV primary screening

C. Cocuzza (Italy)

Challenges and opportunities to implementation of secondary anal cancer prevention programs

J. Palefsky (USA)

SELF-SAMPLING

HPV-testing on self-samples

J. Bonde (Denmark) • M. Arbyn (Belgium)

Evidence on the comparability of self-sampling vs provider-sampling for HPV testing

S. De Sanjosé (Spain) • F. Inturrisi (USA)

HPV self-sampling among transgender and gender diverse individuals

S. Jackson (USA) • A. G. Nyitray (USA)

The utility of urine for improved cervical cancer prevention

R. Steenbergen (Netherlands) • S. Van Keer (Belgium)

Enhancing cervical cancer screening by improving attendance and self-sampling

B. Wisman (Netherlands) • D. Heideman (Netherlands)

VACCINES

Cervical cancer accelerated elimination policies

I. Baussano (France) • E. Franco (Canada)

Single dose HPV vaccination: updates across research domains

A. Kreimer (USA) • J. Kim

Impact of interventions in the post-HPV vaccination world

M. Lehtinen (Finland) • J. Dillner (Sweden)

Long-term follow-up and impact studies for HPV vaccines

M. Poljak (Slovenia) • S. K. Kjaer (Denmark)

Expanding HPV vaccine implementation

MERCK

From gender-neutral vaccination to universal vaccination against HPV: a change of paradigm in public health

P. Bonnani (Italy)

TESTING

HPV-test validation on clinician taken cervical samples

M. Arbyn (Belgium) • M. Poljak (Slovenia)

Global HPV laboratory network

L. S. Arroyo Mühr (Sweden) • K. Cuschieri (UK)

Next generation analysis and bioinformatics

M. Stosic (Norway) • L. S. Arroyo Mühr (Sweden)

Validation of HPV tests for less established indications

M. Poljak (Slovenia)

MANAGEMENT

HPV and reproductive health

K. Louvanto (Finland)

Recurrence of HSIL after treatment

K. Louvanto (Finland)

Colposcopy: discussion on challenging cases

C. Bouchard (Canada)

HPV in older women: Epidemiology, screening and management

F. Carozzi (Italy) • K. Sundström (Sweden)

Targeted therapies of HPV related cancers

M. Von Knebel Doeberitz (Germany)

Management of early-stage cervical cancer and AIS

E. Siegler (Israel)

Point of care testing for cervical screening and management

N. Wentzensen (USA) • K. Cuschieri (UK)

METHYLATION

Clinical indications for DNA methylation analysis for cervical cancer prevention

D. Heideman (Netherlands) • R. Steenbergen (Netherlands)

EPIDEMIOLOGY

Structural and social factors that impact HPV driven cancers

M. Muchengeti (South Africa) • C. Haas (USA)

Evolving patterns in HPV-driven cancers

M. Shiels (USA) • G. Clifford (USA)

LOW- AND MIDDLE-INCOME COUNTRIES

Real-world experience of the implementation of a screen-triage-treat strategy in LMICs

S. De Sanjosé (Spain) • F. Inturrisi (USA)

Cervical cancer in sub-Saharan Africa

M. Muchengeti (South Africa) • S. Kapambwe (South Africa)

SPECIAL POPULATIONS

HPV driven cancer in immunosuppressed populations

E. Engels (USA) • G. Clifford (USA)

Cervical cancer control in underserved populations

M. Goodman (USA) • I. Baussano (France)

ADVOCACY

Public advocacy and awareness campaigns to address barriers in HPV-associated cancer prevention

I. Olkov (France) • S. Hanley (UK)

FRONTIER

Global evidence on HPV involvement in human malignancies at specified non-genital sites

K. Syrjänen (Finland)

CARCINOGENESIS

Update on anogenital carcinogenesis

S. Regauer (Austria) • O. Reich (Austria)

OTHER

Role of HLA in immune evasion of HPV-induced tumors

P. Hillemanns (Germany)

Debate session

T. J. Palmer (UK) • E. Franco (Canada) • K. Cuschieri (UK)

WORKSHOP LUSOFONO

R. Medeiros (Portugal)

M. C. Bicho (Lisboa) • E. Franco (Canada) • Pedro Vieira Baptista (Portugal)

Sessão de Abertura

J. F. Moutinho (Portugal) • M. Passos (Brasil)

Atualidade Epidemiológica: Rastreio HPV e Vacinação no Mundo Lusófono

V. Veloso (Portugal) • M. Passos (Brazil) • M. C. Bicho (Portugal)

O impacto do HPV na Mulher e no Homem: o Mundo Lusófono para além do Colo do Útero

M. Passos (Brazil) • A. Felix (Portugal)

A Investigação e o Mundo Lusófono

J. E. Levi (Brazil) • C. Barbosa (Cape Verde) • Carlos Sousa (Portugal)

O Impacto do HPV na Sociedade

F. Cerqueira (Portugal) • C. Carrilho (Mozambique) • M. Guilherme (Angola)

HPV AND HEAD & NECK FORUM

K. Lang Kuhs (USA) • J. P. Klussmann (Germany) • S. Virani (France) • E. Rettig (USA)

Epidemiology and prevention

K. Lang Kuhs (USA)

Screening for HPV-OPC

T. Waterboer (USA) • Eleni Rettig (USA)

Molecular diagnosis and surveillance

C. J. Brenner (USA) • C. Buchwald (Denmark)

Basic science

S. Virani (France)

Innovations in personalized therapy

J. P. Klussmann (Germany) • E. Rettig (USA)

New discoveries in molecular epidemiology

S. Virani (France)

Recurrent Respiratory Papillomatosis

S. Best (USA)

ARTIFICIAL INTELLIGENCE FORUM

E. Franco (Canada) • J. Monsonogo (France)

N. Wentzensen (USA) • S. Madathil (Canada)
